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Abstract 
Chordoma is a rare malignant tumor characterized by chemoresistance and 
unforeseeable prognosis, originating from notochord remnants that do not 
disappear during development. The apoptotic mechanisms are fundamental for 
notochord cells development and regression, but little is known about the role 
of specific apoptotic pathways. At this purpose we investigated the possible 
implication of Fas/Fasl apoptotic pathway in chordoma tumorigenesis. FASL 
expression was absent, while both FAS anti- and pro-apoptotic isoforms were 
detected in most chordomas analyzed and in U-CH1 cells. These findings, 
besides the prevalent expression of inactive Caspases 8 and 3, suggest that 
Fas/Fasl pathway is impaired in this tumor. The enhancement of apoptosis in U-
CH1 cells by treatment with soluble Fasl indicates that Fas/Fasl pathway can be 
activated in chordoma, suggesting Fas/Fasl as potential pharmacological 
targets. We also hypothesized that Fas/Fasl pathway dysregulation may have a 
role in chordoma onset. To unravel this issue we investigated the function of fas 
and fasl homologs in the zebrafish notochord development. We found that these 
genes were specifically expressed in notochord cells. Morpholino mediated 
knock-down of fas and fasl resulted in abnormal phenotypes mainly showing 
curved tail and altered motility. Notochord multi-cell-layer jumps instead of the 
typical “stack-of-coins” organization, larger vacuolated cells, defects in the 
peri-notochordal sheath structure and in vertebral mineralization have been 
detected in most morphants. In addition, we observed the persistent expression 
of ntla and col2a1a, the zebrafish homologs of the human T gene and COL2A1, 
which were found to be specifically upregulated in chordoma. In conclusion, 
our findings indicate that Fas/Fasl pathway activity can be enhanced in 
chordoma. Moreover, we demonstrated for the first time the involvement of fas 
and fasl in notochord development, differentiation and regression in zebrafish 
suggesting the implication of this pathway in chordoma onset.  
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 CHORDOMA 
Definition and epidemiology 
Chordoma is a rare malignant tumor arising from embryonic remnants of the 
notochord that do not disappear during development of vertebral bodies.  
The incidence of chordoma is of 0,08 per 100000, with predominance in men 
and peak incidence between 50–60 years of age (McMaster et al., 2001), while 
they have very low incidence in patients younger than 40 years, and rarely 
affect children and adolescents (<5% of all chordoma cases) (Wold and Laws, 
1983).  
Chordoma can localize with almost equal distribution in the skull base (32%), 
mobile spine (32,8%), and sacrum (29·2%) (Walcott et al.,2012) and is 
characterized by local invasiveness, tendency for recurrences, with a potential 
to metastasize (Higinbotham et al., 1967), but unlike most malignant 
neoplasms, it is generally slow-growing.  
Chordomas lie in the bone, accounting for 1% - 4% of all malignant bone 
tumors (Bydon et al., 2012), so they initially grow at extradural level with bone 
destruction, having an osteolytic activity, and secondary extension into the 
adjacent soft tissues (Oikawa et al., 2001). 
 
Clinical presentation and histopathology  
This tumor is often clinically silent until the late stages of disease. The clinical 
manifestations vary and depend on location. Skull-base chordomas (SBCs) 
often grow in the clivus and present with cranial-nerve palsies. Depending on 
their size and involvement of the sella, endocrinopathy can also occur (Stark 
and Mehdorn, 2003). Chordomas of the mobile spine and sacrum can present 
with localized deep pain or radiculopathies related to the spinal level at which 
they occur (Fourney and Gokaslan, 2003). Unfortunately, the non-specific 
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nature of these symptoms and insidious onset of pain often delays the diagnosis 
until late in the disease course. Studies show that neurological deficit is more 
often observed in chordomas of the mobile spine than in chordomas of the 
sacrococcygeal region (Boriani et al., 1996).  Chordomas are midline lesions 
and often appear radiographically as destructive bone lesions, with an epicentre 
in the vertebral body and a surrounding soft tissue mass. Unlike osteosarcomas 
and chondrosarcomas of the vertebral column, chordomas locally invade the 
intervertebral disc space as they spread to adjacent vertebral bodies (Chambers 
and Schwinn, 1979). 
Microscopically the tumor is characterized by the physalipherous cells, the 
typical notochordal cells with a nucleus surrounded by large vacuoles. 
Chordomas manifest as one of three histological variants: classical 
(conventional), chondroid, or dedifferentiated. Classical chordomas appear as 
soft, gray-white, lobulated tumors composed of groups of cells separated by 
fibrous septa. They have round nuclei and an abundant, vacuolated cytoplasm 
described as physaliferous (having bubbles or vacuoles). Unlike classical 
chordoma, chondroid chordomas histologically show features of both chordoma 
and chondrosarcoma, a malignant cartilage-forming tumor.  
Classically, chordomas were pathologically identified by their physaliferous 
features and immuno-reactivity for the protein S-100 and epithelial markers 
such as epithelial membrane antigen (MUC1) and cytokeratins. However, until 
recently, distinguishing between chondroid chordomas and chondrosarcomas 
was challenging because of their shared S-100 immunoreactivity, making it 
difficult to interpret cytokeratin expression on small biopsies (Henderson et al., 
2005). Several groups have postulated that the notochord developmental 
transcription factor Brachyury could be the novel discriminating biomarker for 
chordomas. This hypothesis was validated with a tissue-microarray-based 
analysis that assessed 103 skull-base, head and neck chondroid tumors. In that 
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study, Oakley and colleagues identified Brachyury as a discriminating 
biomarker of chordomas, and when combined with cytokeratin staining, 
sensitivity and specificity for detection of chordoma was 98% and 100%, 
respectively (Oakley et al., 2008). Brachyury staining to discriminate 
chordomas from other chondroid lesions has therefore become integral in the 
pathological work-up during diagnosis (Figure 1). Moreover, also the lack of 
IDH1 or IDH2 mutation in chordoma helps to differentiate it from other 
cartilaginous tumors, especially in differentiating the skull base 
chondrosarcoma from chordoma (Szuhai and Hogendoorn, 2012). 
In a recent characterization of chordoma tumors and cell lines, other genes were 
found differentially expressed in this tumor; among them the alpha collagen 
type II (COL2A1) was significantly overexpressed (Bruderlein et al., 2010). 
 
 
Figure 1. Immunohistochemical characterisation of human chordoma tissue 
Intraoperatively obtained chordoma tissue with physaliferous phenotype; haematoxylin and 
eosin (H&E) stained, frozen tissue smear (A,B,C). Intraoperatively obtained chordoma tissue 
with physaliferous phenotype; H&E stained, formalin-fi xed tissue (D,E,F). Chordoma tissue is 
positive for S-100β in A, for cytokeratin AE1/AE3 in B, and for brachyury in C; 
immunohistochemistry with diaminobenzidine chromogen  
Lancet Oncol. 2012 Feb;13(2):e69-76. doi: 10.1016/S1470-2045(11)70337-0 
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Prognosis 
Extent of resection, previous treatment, adjuvant proton beam therapy and the 
karyotype are thought to influence the prognosis of chordoma (Colli and Al-
Mefty, 2001). Despite the possibility of a long progression-free survival after 
gross total or subtotal resection and radiation therapy, ultimately the majority of 
patients will experience recurrence and will die of local progression of their 
disease. It also appears, however, that chordomas that have been resected to the 
same extent and that received post-operative radiotherapy might exhibit 
different rates of re-growth (Gagliardi et al., 2012). This result supports the 
hypothesis that the recurrence rate of chordomas might be dependent on 
variables other than the extent of resection and the postoperative radiotherapy. 
Several studies investigated the classic pathological paradigms in relation to the 
biological and clinical behavior of chordomas. Matsuno et al. studied the 
immunohistochemical expression of MIB-I, p53, cyclin D1 and identified these 
markers as important predictors of recurrence (Matsuno et al., 1997). It was also 
demonstrated that the proliferative potential of chordoma was correlated with 
the combination of p53 overexpression, anaplasty, high-grade atypia and 
diffuse proliferation (Naka et al., 2005; Naka et al., 2009; Naka et al., 2008). 
The expression of telomerase transcriptase mRNA (hTERT) and mutation of 
p53 were associated with the risk for early recurrence (Pallini et al., 2003). 
More recently, the occurrence of 1p36 loss of heterozygosty (LOH) was 
frequently observed in skull base chordomas (75%) and the absence of LOH 
was associated with a mild prognosis, indicating 1p36 LOH as a potential 
prognostic marker to be validated in a larger casuistry (Longoni et al., 2008; 
Miozzo et al., 2000; Riva et al., 2003). 
Despite all the observed associations between clinical outcome and molecular 
features of chordomas, no validated molecular markers are available to monitor 
the tumor progression. Therefore, there is the need of identifying suitable 
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prognostic markers to be considered for the clinical approach and the setting-up 
of targeted treatment protocols. 
 
Treatment 
Major role in the treatment of chordomas is played by extensive surgical 
resection when possible. Goals of surgery are to remove as much neoplastic 
tissue as possible and to preserve or improve patient's functional status 
(Gagliardi et al., 2012). An important role in the management of chordomas is 
played by high-dose radiotherapy, which provides a good tumor control. 
Chordomas are considered relatively resistant to conventional radiotherapy and 
the most common delivery methods applied in their treatment include proton 
beam radiotherapy, high-dose radiotherapy and radiosurgery using Gamma 
Knife and Cyber- Knife. Radiotherapy provides better local control when 
administered postoperatively than when delivered after recurrence following 
surgical resection. Main delivery methods are, radiosurgery and radioactive 
sources (Gagliardi et al., 2012). 
Unfortunately, systematic review of the literature found chordomas to be 
insensitive to conventional chemotherapies (Walcott et al., 2012). Nevertheless, 
molecular profiling of chordomas has revealed that they express the Platelet-
Derived Growth Factor Receptor (PDGFR)B, PDGFRA, and KIT receptors, in 
both tumor and stroma cells, and chemotherapy with imatinib mesylate (IM), a 
PDGFR inhibitor, might represent a therapeutic option in patients with 
recurrent chordoma not even eligible for surgery or radiotherapy (Gagliardi et 
al., 2012). The anti-tumor activity of IM was documented by the detection of a 
decrease in the size of the tumor and/or tumor stabilization with altered tumor 
density (Casali et al., 2004), notwithstanding the complete remission of the 
mass tumor was never observed. Furthermore the association of IM with other 
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chemotherapeutic agents, such as mTOR inhibitor molecules, showed to be 
effective in the treatment of IM-resistant chordomas (Stacchiotti et al., 2009; 
Stacchiotti et al., 2013).  
As tumor characteristics are further elucidated, additional molecular pathways 
have been targeted. In a series of 12 patients with chordoma, strong expression 
of Epidermal Growth Factor Receptor (EGFR) and c-MET was described and it 
was reported the response to cetuximab, gefitinib and erlotinib, three drugs 
designed to inhibit the EGFR pathway (Singhal et al., 2009). A recent analysis 
of 70 chordoma samples showed activation of phosphorylated-Signal-
Transducer and Activator of Transcription 3 (STAT3), a transcription factor 
known to be activated in several human cancers and associated with poor 
prognosis. The use of STAT3 inhibitors in chordoma cell lines in vitro showed 
strong inhibition of cell growth and proliferation (Yang et al., 2009a).  
Despite these preliminary but encouraging data, the evaluation of the reported 
pharmacological targets or the identification of new ones,  represent a challenge 
for the research in this field, aimed at setting up an effective chemotherapy for 
the treatment of chordoma. 
 
Brachyury: the pathognomonic marker of chordoma 
The maintenance of the notochordal tissue characteristics in chordoma is 
confirmed by microscopic features, the localization of the tumor along the axial 
skeleton, and the expression of similar transcription factors. Among them, the 
most significant is the transcription factor T (encoding for Brachyury), the 
founder member of the T-box family involved in notochord development 
(Glickman et al., 2003; Salisbury, 2001; Salisbury et al., 1993) and recently 
identified as the pathognomonic marker for chordoma (Nelson et al., 2012).  
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The T-box genes encode a family of transcription factors sharing a 
characteristic sequence similarity within the DNA-binding domain (T-domain). 
To date, 18 different mammalian T-box genes have been identified, many of 
which have orthologous in a wide variety of multicellular organisms (Showell 
et al., 2004). Brachyury is localized to the nucleus, binds DNA in a sequence-
specific manner, and can regulate transcriptional levels of heterologous and 
downstream target genes in several different contexts (Showell et al., 2004).  
This protein functions as a transcriptional activator of mesoderm-specific genes, 
indeed its expression is required for the specification of mesodermal identity, 
representing one of the key molecules regulating notochord formation 
(Henderson et al., 2005).  
Brachyury was the first molecule identified which specifically links notochord 
with chordoma. Extensive investigations were performed on various normal 
tissues, organs and several tumor entities for the expression of Brachyury, 
including various types of carcinomas, sarcomas, haematological malignancies, 
germ cell tumors, and benign lesions. Expression of Brachyury was rarely 
observed in normal testis (> 20%), and a similar frequency was observed in 
germ cell tumor of testis. A specific and highly prevalent expression of 
Brachyury was observed, as well as in chordoma, in haemangioblastoma of the 
central nervous system (CNS) (100% of the cases) (Tirabosco et al., 2008). This 
tumor is likely derived from a mesodermal sub-population, with differentiation 
capacity towards both endothelial cells and haematopoietic cells, in line with 
the role of Brachyury in the development of the posterior mesoderm including 
haemangioblasts formation (Szuhai and Hogendoorn, 2012). Moreover, the 
expression of Brachyury has been detected in benign notochord cells tumor of 
extraosseous origin, which is the benign tumor which leads to malignant 
chordoma (Deshpande et al., 2007; Yamaguchi et al., 2008).  
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High-resolution array-CGH profiling of familial chordoma cases revealed 
duplication of the chromosome 6q27 region, with the smallest duplicated region 
containing the T gene region only (Yang et al., 2009b). In a follow-up study of 
sporadic chordomas, however, it was shown that duplication or amplification of 
the T locus was present in less than 5% of investigated chordoma cases 
(Presneau et al., 2011). No mutations of the T gene were identified in chordoma 
specimens (Shalaby et al., 2009; Yang et al., 2009b). These results were in line 
with the deleterious effect of mutant protein on embryonic differentiation 
leading to the Brachyury (short tale) phenotype or lethality in cases of 
homozygous mutation in different animal models.  
Diverse pathways have been demonstrated to regulate Brachyury expression 
during evolution, such as Wnt/-catenin, TGF-/Nodal/activin, BMP, and FGF; 
among them the most relevant is activated by the Fibroblastic Growth Factor 
Receptors (FGFRs) through RAS/RAF/MEK/ERK and ETS2 in ascidian, 
Xenopus and zebrafish, although little is known about its regulation in 
mammals. The expression of the members of this pathway was investigated in 
chordoma samples and most of them expressed at least one of the FGFRs, 
nevertheless no conclusive association was identified between Brachyury and 
FGFRs expression in chordoma (Shalaby et al., 2009). 
At a functional level, the silencing of Brachyury induced growth arrest in a 
chordoma cell line (Presneau et al., 2011), while its overexpression, observed in 
the human pancreatic cell line PANC-1 which does not express it, resulted in 
enhanced proliferation, motility and invasiveness (Fernando et al., 2010). 
Moreover, an integrated functional genomics approach showed that the 
silencing of Brachyury in the U-CH1 chordoma cell line altered the expression 
of several direct targets and of other targets that indirectly influenced. 
Interestingly, Brachyury expression was not detected in de-differentiated 
chordomas, pointing its loss as a form of tumor progression, marking the 
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evolution from a differentiated chordoma, similar to notochord, to a de-
differentiated form of the tumor (Jambhekar et al., 2010). 
These findings pinpoint Brachyury as a master regulator of an elaborate 
oncogenic transcriptional network encompassing diverse signaling pathways 
including components of the cell cycle, and extracellular matrix components 
(Nelson et al., 2012). All these evidences taken together, identify Brachyury as 
the diagnostic marker for chordoma and as a strong potential target for the 
development of new specific therapies, but the causes at a developmental and at 
molecular levels of its expression in chordoma are still unclear. In fact, the 
finding of the T gene expression in this tumor might be due to its deregulated 
expression in notochord cells leading to chordoma, alternatively the defects in 
notochord regression may maintain proliferating notochord cells which express 
the T gene, or both of these possibilities (Szuhai and Hogendoorn, 2012).  
Therefore, studies of T gene expression regulation are necessary to clarify 
chordoma tumorigenesis, but also parallel studies aimed at identifying further 
mechanisms possibly involved in the biology of this tumor and in the notochord 
development/regression must be pursued.  
 
NOTOCHORD 
Definition 
The notochord is an embryonic midline rod-like shaped structure common to all 
members of the phylum Chordata. Accordingly, it serves as the axial skeleton 
of the embryo until other elements, such as the vertebrae, form.  
In some vertebrate clades, such as the agnathans (lampreys), cephalochordates 
and in primitive fish, such as sturgeons, the notochord is essential for 
locomotion and persists throughout life (Stemple, 2005). For the ascidian 
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(tunicate) invertebrate chordates, the notochord exists during embryonic and 
larval free-swimming stages, providing the axial structural support necessary 
for locomotion (Urano et al., 2003).  
In higher vertebrates, the notochord exists transiently and becomes ossified in 
regions of forming vertebrae and persists in the center of the intervertebral 
discs, in a structure called the nucleus pulposus (Linsenmayer et al., 1986; 
Smits and Lefebvre, 2003). In these vertebrate clades, it has two important 
functions. First, the notochord is positioned centrally in the embryo with respect 
to both the dorsal-ventral (DV) and left-right (LR) axes. This structure produces 
secreted factors that signal to all surrounding tissues, providing position and 
fate information and specifying ventral fates in the central nervous system. The 
notochord also controls aspects of LR asymmetry, inducing pancreatic fates, 
controlling the arterial versus venous identity of the major axial blood vessels 
and specifying a variety of cell types in forming somites (Christ et al., 2004; 
Danos and Yost, 1995; Fouquet et al., 1997; Goldstein and Fishman, 1998; 
Lohr et al., 1997; Munsterberg and Lassar, 1995; Pourquie et al., 1993; Yamada 
et al., 1993). 
 
Embryogenesis and functions  
In vertebrates, the notochord arises from the dorsal organiser, a region of a 
vertebrate gastrulae that, when transplanted into prospective lateral or ventral 
regions of a host embryo, induces the formation of a second embryonic axis, 
while only contributing to notochord and prechordal mesendoderm (Harland 
and Gerhart, 1997). In amphibians, this region is the dorsal lip of the 
blastopore. In other species, homolog structures have been found: the 
embryonic shield of teleost fish, Hensen’s node in the chick and the node of 
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mouse embryos all possess essentially the same activities as amphibian dorsal 
organiser (Beddington, 1994).  
Leading to notochord formation, the first major transition occurs from dorsal 
organiser to chordamesoderm. During early gastrula stages, the 
chordamesoderm, which is the direct antecedent of the notochord, becomes 
morphologically and molecularly distinct from other mesoderm. Cellular 
rearrangements involving the mediolateral intercalation and convergence of 
cells towards the dorsal midline, force the chordamesoderm into an elongated 
stack of cells. Genetic screens in zebrafish have identified the gene floating 
head (flh) and the locus bozozok (where the gene dharma is mapped– Zebrafish 
Information Network), as being essential for this transition to occur (Amacher 
and Kimmel, 1998; Fekany et al., 1999; Solnica-Krezel et al., 1996; Talbot et 
al., 1995). bozozok mutant embryos lack a morphologically distinct shield, and 
both bozozok and floating head (flh) mutant embryos fail to form a notochord 
(Fekany et al., 1999; Talbot et al., 1995). Expression of flh mRNA is a good 
prospective marker of notochord fate (Gritsman et al., 2000). In early gastrula 
zebrafish embryos, flh is expressed superficially within the organiser region. 
Simultaneously, another homeodomain-encoding gene, goosecoid (gsc) is 
expressed in deep organiser tissues. While gsc was found to be involved in the 
induction of the rostral part of the axis, flh was found to predominantly regulate 
the formation of trunk and tail (Saude et al., 2000).  
Another mechanism that occurs before to the one just described is the induction 
of mesoderm. Many of the molecules involved in mesoderm induction are the 
Nodal pathway- and the Nodal-related pathway- proteins. Importantly, the 
response of animal cap cells to Nodal is graded, so that different levels of Nodal 
signalling lead to different mesodermal and axial mesendodermal fates. High 
levels of Nodal signaling specify the deep gsc-expressing cell fates, while lower 
levels specify flh-expressing prospective chordamesoderm (Gritsman et al., 
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2000). Therefore, Nodal signalling pathway is required for specification of 
dorsal mesendodermal fates and for early mesoderm induction. It is not, 
however, required for dorsal specification or neural induction (Gritsman et al., 
2000). 
After neurulation the notochord lies beneath the floor plate of the neural tube, 
above the endoderm, and between the paired somites that extend the length of 
the trunk and the tail (Cunliffe and Ingham, 1999). 
As development proceeds, chordamesoderm cells acquire a thick extracellular 
sheath and a vacuole. Osmotic pressure within the vacuole acts against the 
sheath, gives the notochord its characteristic rod-like appearance, and provides 
mechanical properties that are essential for the proper elongation of embryos 
and for the locomotion of invertebrate chordates and many vertebrate species 
(Adams et al., 1990; Koehl, 1999). The transition from chordamesoderm to 
mature notochord requires a host of genes that have been identified in zebrafish 
genetic screens (Odenthal et al., 1996; Stemple et al., 1996). 
Critical to its function, the notochord expresses transcription factors encoded by 
the brachyury, HNF-3b and floating head genes (Smith et al., 1991; Talbot et 
al., 1995), as well as the secreted factor sonic hedgehog (Ingham, 1995).  
Studies in the mouse, Xenopus, and zebrafish have demonstrated that the 
trancription factor brachyury is required for differentiation of axial midline 
mesoderm into notochord as well as for the formation of posterior mesodermal 
tissues (Cunliffe and Ingham, 1999). It regulates the expression of several 
genes. These include extracellular matrix proteins, cell adhesion molecules, and 
cytoplasmic signaling pathway components.  
The notochord has several roles in patterning surrounding tissues, and among 
them also the neural tube. A series of experiments involving both the 
transplantation and the removal of the notochord during development showed 
that the notochord can signal the formation of the floor plate, which is the 
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ventral-most fate of the spinal cord (Placzek et al., 2000; van Straaten et al., 
1989). Among the signals secreted by the notochord are the Hedgehog (Hh) 
proteins. Sonic Hedgehog, in particular, induces a range of ventral spinal cord 
fates in a graded fashion while simultaneously suppressing the expression of 
characteristically dorsal genes. Reinforcing and maintaining earlier 
developmental events, notochord signals are also involved in establishing LR 
asymmetry (Danos and Yost, 1995; Lohr et al., 1997). In teleosts, notochord-
derived Hh signals control the formation of the horizontal myoseptum, as well 
as specifying slow-twitch muscle fates (Barresi et al., 2000) (Figure 2). 
Although the patterning roles of the notochord are essential for normal 
vertebrate development, the notochord also has an essential structural role. The 
notochord is the main axial skeletal element of the chordate early embryo; 
without a fully differentiated notochord, embryos fail to elongate (Stemple, 
2005). For many species, this results in the inability to swim properly, to escape 
predation and to feed (Stemple et al., 1996).  
There is some relationship between notochord differentiation and the presence 
of the basement membrane. This is likely to involve signalling from the 
basement membrane to chordamesoderm. The state of differentiation can be 
determined by analysis of gene expression. For example, echidna hedgehog, 
which is a zebrafish homologue of mammalian Indian hedgehog, is normally 
expressed in chordamesoderm, but when the notochord differentiates and 
vacuoles inflate, echidna hedgehog expression is extinguished (Currie and 
Ingham, 1996).  
Consistent with its structural role in vertebrate development, the notochord 
shares many features with cartilage. It expresses many genes that are 
characteristic of cartilage, such as those that encode type II and type IX 
collagen, aggrecan, Sox9 and chondromodulin (Dietzsch et al., 1999; Sachdev 
et al., 2001; Zhao et al., 1997). There is, however, one clear difference between 
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chondrogenesis and notochord formation. Chondrocytes normally secrete a 
highly hyrdrated extracellular matrix, which gives cartilage its main structural 
properties (Knudson et al., 2000). By contrast, notochord cells produce a thick 
basement membrane sheath, and retain hydrated materials in large vacuoles 
(Parsons et al., 2002). These vacuoles allow notochord cells to exert pressure 
against the sheath walls, which give the notochord its structural properties 
(Koehl, 1999). The ultimate fate of the notochord also emphasizes the 
relatedness of notochord and cartilage. During endochondral bone formation, 
the type II collagen-rich extracellular matrix of cartilage is deposited with type 
X collagen, which signals the eventual replacement of cartilage by bone 
(Aszodi et al., 1998; Linsenmayer et al., 1986). Similarly, during the 
development of vertebrae, notochord that runs through the middle of each 
vertebra first expresses type II and type X collagen and is then replaced by 
bone(Linsenmayer et al., 1986). Between the vertebrae, the notochord does not 
express type X collagen and is not replaced by bone, but becomes the centre of 
the intervertebral disc – the nucleus pulposus (Aszodi et al., 1998; Smits and 
Lefebvre, 2003). Thus, notochord can become ossified in a fashion similar to 
cartilage. Consistent with this view, in mutant mice that lack type II collagen, 
the notochord is not replaced by bone, presumably because the type II collagen 
network is required for proper deposition of type X collagen. 
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Figure 2. Structural aspects of the notochord. (A) A lateral view of a living zebrafish tail at 
24 hpf, showing the main features of the notochord. Dorsal to the notochord is the floor plate, in 
the ventral-most part of the forming spinal cord. Ventral to the notochord is the hypochord. (B) 
A schematic diagram of lateral and cross-sections of the notochord, showing the floor plate and 
hypochord acting as cables running along the top and bottom of the notochord. (C) As well as 
the notochord, the floor plate and hypochord express type II collagen. cc, central canal; fp, floor 
plate; hy, hypochord; no, notochord; nt, neural tube. 
Development. 2005 Jun;132(11):2503-12 
 
Regression 
During the embryonic development, notochord regresses and is replaced by 
bone.  
In teleosts, the development of the vertebral bodies begins with the 
mineralization of the notochord that presents an Extra Cellular Matrix (ECM) 
similar to the cartilage, which is rich in proteoglycans and type II collagen, and 
is covered by a thin layer of elastin. Several evidence suggests that the 
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notochord cells themselves induce such mineralization (Bensimon-Brito et al., 
2010; Grotmol et al., 2006). The mineralized bone tissue is placed in the 
notochord region only during the second phase of the vertebral bodies 
formation (Grotmol et al., 2006). In this infraclass of vertebrates, cartilage, 
unlike higher vertebrates (such as mammals), is not involved in the initial 
formation of bone tissue (Knopf et al., 2011).  
In the intervertebral discs, notochord-like cells have a role in maintaining the 
integrity of the disk (Erwin and Inman, 2006): these cells are localized in the 
nucleus pulposus. As a matter of fact,  the expression of proteoglycans, the 
major matrix proteins of the nucleus pulposus of the intervertebral discs, seems 
to depend on factors secreted by notochordal cells of the intervertebral disks 
(Aguiar et al., 1999).  
The development of the vertebral bodies in zebrafish begins with the formation 
of the perichordal center (also known as cordacentra), a mineralized structure 
shaped as a ring surrounding the notochord. The perichordal center is formed by 
segments in the anterior-posterior direction (Du and Dienhart, 2001; Haga et al., 
2009) (Figure 3 A-E). The vertebrae and intervertebral discs are distinguishable 
at the stage of 15 Days Post Fertilization (dpf), 7 mm, and the notochord cells-
like in the intervertebral discs are largely vacuolated and are clearly visible in 
larvae startign from 15 dpf.  Within 21 dpf (9 mm), the size of the disks 
increases significantly and at the stage of 47 dpf the discs are occupied by two 
large vacuoles surrounded by a layer of small cells, and separated by two layers 
of cells in the center. The structure called notochordal center is located in the 
center of the vertebrae; it is probably the remnant of the notochord and the large 
vacuoles of the intervertebral disks  are connected to this channel (Figure 3 F-I) 
(Haga et al., 2009).  
Differently to the intervertebral discs, the vertebral bodies are formed for the 
most part from calcified bone tissue.  
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Figure 3. Analyses of notochord segmentation and vertebral formation. Calcein staining 
shows notochord segmentation by formation of calcified chordacentra from the anterior to the 
posterior notochord. (A) chordacentra formation (arrows) in the anterior region of the notochord 
at 11 dpf. (B) chordacentra appears in the posterior region of the notochord by 13 dpf. (C) the 
width of individual chordacentra expands significantly by 15 dpf. Vertebral bodies (arrows) are 
clearly developed in zebrafish larvae at 18 (D) and 21 (E) dpf. Histological analyses of H&E 
staining shows the sagittal views of the vertebral column at 12 (F), 15 (G), 21 (H) and 47 (I) 
dpf. (F) The vertebral column is primarily occupied by large vacuolated notochord cells at 
12 dpf. Intervertebral discs (arrowhead) appear in a segmented manner at 15 (G), 21 (H), and 47 
(I) dpf. The intervertebral disc contains large vacuolated notochord-like cells. Arrows indicate a 
notochordal canal in the center of the vertebral body that connects with the intervertebral discs. 
Scale bars (A-C) ~75 μm; (D,E) ~100 μm; (F-H) ~50 μm 
Transgenic Res. 2009 Oct;18(5):669-83. doi: 10.1007/s11248-009-9259-y 
 
Otherwise, during embryonic development of mammals, sclerotomal cells 
migrate towards the notochord and are arranged around it forming a continuous 
perichordal tube. It is initially non-segmented and is not in direct contact with 
the notochord, but is separated by a fibrous sheath of notochordal origin. This 
axial mesenchyme subsequently acquires a metameric structure of alternating 
regions consisting in condensed cells groups and in non-condensed cells 
groups. The condensed portions give rise to the annulus fibrosus of the 
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intervertebral discs, while the non-condensed perichordal cells form the 
cartilage primordia of the vertebral bodies (Theiler, 1988).  
During the embryonic development, the inner part of the annulus fibrosus 
differentiates into hyaline cartilage-like tissue and forms an uninterrupted 
cartilage column surrounding the notochord together with the vertebral bodies. 
Concurrently with the chondrification process, the notochord regresses in the 
areas where vertebral bodies will develop, while it expands between the 
vertebrae to form the nucleus pulposus (Theiler, 1988).  
Many transcription factors, growth factors, and extracellular matrix molecules 
play a conserved role during evolution in the development of the notochord and 
intervertebral discs. The transcription factors Sox5 and Sox6 are required for 
the survival of the notochord and the development of the nucleus pulposus 
(Smits and Lefebvre, 2003), while the type II collagen, is required for the 
formation of the intervertebral discs (Aszodi et al., 1998; Barbieri et al., 2003). 
The Retinoic acid (RA) is another signal molecule involved in the development 
of the vertebral disc.  
In mammals, after birth, the nucleus pulposus of notochordal origin undergoes 
to a cartilage transition (Rufai et al., 1995). The notochordal cells which are 
present in the nucleus pulposus are progressively replaced by chondrocytes 
from cartilage plates (Kim et al., 2003). During this change the notochord cells 
gradually regress. In humans, this transition may be completed within the 
second decade (Buckwalter, 1995).  
To date, little is known about the molecular mechanisms that lead to the 
regression of notochord cells: Malikova et al., demonstrated that apoptosis is 
necessary for the proper morphogenesis of the notochord during the formation 
of the anterior-posterior axis in embryos of Xenopus laevis. They detected 
apoptotic cells in the notochord starting from the neural groove stage and 
increasing in number as the embryo developed. The dying cells were distributed 
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in an anterior to posterior pattern, correlated with notochord extension through 
vacuolization. The inhibition of apoptosis in vivo decreased the length of the 
notochord which also appeared severely kinked. The notochord progressively 
lacked any recognizable structure, although notochord markers were expressed 
in a normal temporal pattern, moreover the somites were severely disorganized 
(Malikova et al., 2007). Their results indicate that apoptosis is required for 
normal notochord development during the formation of the anterior posterior 
axis and possibly for its consequent regression.  
Interestingly, Kim et al. (2005) demonstrated that the apoptotic pathway 
mediated by Fas and Fasl is a mechanism through which notochord cells of the 
adult nucleus pulposus regress in rat. The coexpression of Fas and Fasl by the 
same cell has been implicated in the regulation of physiological cell turnover, 
the maintenance of immune privileged status and the protection of some tissues 
against potential malignant cells. Thus, Fas and Fasl coexpression by the 
notochord cells seems to have similar biological functions in the notochordal 
nucleus pulposus (Kim et al., 2005). The notochord cell population probably 
controls its proliferative status through the pathway mediated by fas and fasl 
through an autocrine or paracrine counterattack (Kim et al., 2005).  
Fasl is an important effector molecule of cell mediated cytotoxicity against 
transformed cells. Therefore, resistance to Fas mediated apoptosis could 
provide a malignant cell with a selective advantage in its attempt to evade 
immune surveillance. Indeed, resistance to Fas crosslinking has been reported 
in a large percentage of cancer cell lines, and appears to be more common in 
lines originating from high-grade tumors. Several mechanism of resistance to 
Fas-mediated apoptosis have been suggested, including downregulation of Fas 
expression, mutations and deletions of Fas gene and the production and release 
of soluble decoy receptors that binds and inactivate Fasl (Poulaki et al., 2001).   
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Fas AND Fas ligand 
Apoptotic pathway mediated by Fas and Fasl 
Fas Ligand (Fasl) is a member of the tumor necrosis factor (TNF) superfamily 
that induces apoptosis in susceptible cells upon cross-linking of its own 
receptor, Fas (Apo-1/CD95), member of TNF receptors (TNFR) superfamily. 
The autocrine–paracrine interaction between Fas and Fasl results in the 
trimerization and activation of the Fas receptor. Fas intracellular death domain 
(DD) binds to the Fas-associated DD-containing protein (FADD) forming the 
death-inducing signaling complex (DISC). There are two different pathways 
downstream of Fas. In so called type I cells, the death signal is propagated by a 
caspase cascade initiated by the auto-activation of large amounts of caspase 8 
recruited by FADD and which in turn initiates downstream activation of 
caspase- 3, -6, and -7. In type II cells, however, very little DISC is formed, so 
the caspase cascade cannot be propagated directly and has to be amplified via 
mitochondria. In the mitochondrial pathway, the apoptosome forms when 
intracellular signals trigger the release of cytochrome-c, which triggers the 
assembly of the Apaf-1/caspase-9 holoenzyme and in turn activates caspase-3 
(Fig 4). The effector Caspases, Caspase-3, -6, and -7, cleave several different 
cellular substrates causing irreversible morphological changes in cells and 
nuclei associated with apoptosis (Figure 4) (Scaffidi et al., 1998; Scaffidi et al., 
1999). Each step in the cascade is tightly controlled by intracellular factors that 
can inhibit the apoptotic pathway either at the “initiator” or “effector” level 
(Villa-Morales and Fernandez-Piqueras, 2012).  
The Caspases are a family of cysteine proteases that cleave their substrates after 
aspartic acid residues. So far, 14 members of the caspase family have been 
identified. The Caspases involved in apoptosis are divided into two subfamilies, 
the initiator (Caspase 2, 8, 9, and 10) and executioner Caspases (caspase 3, 6, 
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and 7) (Li et al., 2010). Caspases are constitutively present within cells as latent 
zymogens or precursors that require proteolysis to achieve their active, 
heterodimeric configuration (Sharma et al., 2000). 
Multiple mechanisms regulate the sensitivity of Fas-expressing cells to Fas-
induced apoptosis, including alternative splicing of FAS pre-mRNA. The 
inclusion of FAS exon 6 results in the synthesis of the mRNA encoding the 
proapoptotic form of the FAS receptor, while mRNAs lacking exon 6 encode 
soluble form of the receptor, which, sequestering Fasl, lead to a reduction of 
Fas signaling, inhibiting apoptosis (Izquierdo, 2011; Izquierdo and Valcarcel, 
2007).  
 
 
 
Figure 4. Intrinsic and extrinsic Caspase-dependent apoptotic pathways. The extrinsic 
pathway is activated by the membrane receptor Fas that, following interaction with its ligand 
Fasl activates Caspase 8, which in turn activates the effector caspase 3. The intrinsic pathway 
also involves the mitochondrion, determining the release of cytochrome C, the activation of 
Capsase 9 and in the downstream the Capsase 3. Both the extrinsic pathway that the intrinsic 
involve the activation of caspase 3 that cuts activating various substrates that determine 
irreversible morphological changes in the nucleus and cytosol leading to apoptosis. 
Apaf1, apoptotic protease activating factor-1, ATP, adenosine triphosphate; FADD, Fas-
associated death domain. 
http://pi-patologia.blogspot.it/ 
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On the other hand, diverse mechanisms play a role in the control of FAS and 
FASL expression. Recently, FAS (rs1800682 and rs2234767) and FASL 
(rs763110) functional SNPs have been identified. In different populations 
specific alleles were demonstrated to be associated with FAS and FASL 
dysregulation in several tumors such as breast cancer, squamous cell carcinoma 
of the larynx and hypopharynx, epithelial ovarian cancer and non-small cell 
lung cancer (Girnita et al., 2006; Hashemi et al., 2012; Li et al., 2013; Park et 
al., 2009; Wang et al., 2013; Wu et al., 2013; Xiang et al., 2012). The  
rs1800682 FAS SNP is situated within the Signal Transducers and Activators of 
Transcription 1 (STAT1) binding element, and the G/G genotype reduces the 
promoter activity (Sibley et al., 2003). The rs2234767 FAS SNP is located 
within the Stimulatory protein 1 (Sp1) Transcription Factor binding site of the 
FAS gene, and  the A/A genotype was associated to the diminution of the 
promoter activity (Huang et al., 1997). The rs763110 FASL C/C genotype, 
located within the binding motif for the transcription factor CAAT/ enhancer 
binding protein β, is associated with a higher FASL expression then the C/T and 
T/T genotypes (Wu et al., 2003). 
Also post-transcriptional mechanisms play a role in the regulation of FAS and 
FASL expression. Several microRNA were demonstrated to directly regulate 
FAS expression, and among them miR-20a was shown to be involved in the 
increase of metastatic potential of osteosarcoma (Huang et al., 2012). miR-196b 
also regulates FAS expression and its upregulation was involved in FAS 
repression in MLL-leukemia (Li et al., 2012). FASL is known to be targeted by 
miR-21, which has been shown to be involved in tumor progression and its up-
regulation was correlated with a lower cancer survival rate in different tumors 
(Frezzetti et al., 2010; Zhu et al., 2012).  miR-21 has been shown to be a 
biomarker for chemoresistance and clinical outcome following adjuvant 
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therapy, and it could be a potential pharmacological target to be evaluated in 
cancer (Frezzetti et al., 2010).  
 
Extrinsic apoptotic pathway conservation during evolution 
The two distinct signaling mechanisms, the cell-intrinsic and cell-extrinsic 
pathways, control the activation of the proapoptotic caspase family in mammals 
(Danial and Korsmeyer, 2004). While components of the intrinsic pathway 
apparently exist in all metazoans, the extrinsic pathway is a more recent 
evolutionary development (Eimon et al., 2006). No TNF or TNFR superfamily 
members have been found to date in Caenorhabditis elegans. In Drosophila, a 
single TNF ligand (Eiger) and its associated receptor (Wengen) induce 
apoptosis indirectly, by activating the caspase-9 homolog DRONC through the 
c-Jun N-terminal kinase (JNK) pathway; Drosophila homologs of caspase-8 
(DREDD) and FADD do not appear to play a role in the extrinsic apoptotic 
pathway (Igaki et al., 2002; Kanda et al., 2002). DD-containing TNFRs have 
been reported exclusively in vertebrates, with examples in teleost (Eimon et al., 
2006), avian (Brojatsch et al., 2000), and mammalian species (Locksley et al., 
2001). Interestingly, not all DD-containing TNFRs are dedicated activators of 
the extrinsic apoptosis pathway. For example, mammalian TNFR1 signals 
through the adaptor TNFR-associated DD (TRADD) and its principal role in 
vivo is NF-kB activation, which inhibits apoptosis (Varfolomeev and 
Ashkenazi, 2004). Only DR4, DR5, and Fas have DDs that directly bind 
FADD.  
In mammals, the extrinsic pathway plays an important role in regulating the 
immune system (Varfolomeev et al., 1998).  As a matter of fact, the importance 
of Fas/Fasl mediated apoptosis is emphasized by the effects of the gld 
(generalized lymphoproliferative disease) and lpr (lymphoproliferation) 
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mutations, which are mutations respectively of the murine Fas ligand and Fas 
genes (Adachi et al., 1993; Watanabe-Fukunaga et al., 1992). Both of these 
mutations cause an age-related autoimmune syndrome that is characterized in 
part by the production of autoantibodies and the peripheral accumulation of 
large numbers of atypical double-negative (DN) T cells, leading to 
lymphadenopathy and splenomegaly (Cohen and Eisenberg, 1991). The lack of 
a functional fas/fasl- mediated pathway of apoptosis is believed to produce this 
autoimmune syndrome as a result of an impairment in both the clonal deletion 
of autoreactive lymphocytes in the periphery and the elimination of previously 
activated lymphocytes (Russell and Wang, 1993). Mice in which the gene for 
Fas has been deleted develop an autoimmune syndrome that is similar to that 
displayed by the lpr and gld mice (Adachi et al., 1995; Senju et al., 1996) and 
humans carrying homozygous mutations in the FAS gene also develop an 
autoimmune lympho- proliferative disorder.  
Studies carried on FADD- and Caspase-8- knockout mice suggest that the 
extrinsic pathway also may be required during embryogenesis. In fact,  
knockout mice of the extrinsic pathway inhibitor c-FLIP (cellular FLICE 
inhibitory protein) all die in utero between embryonic days 10.5 and 12.5 (Yeh 
et al., 2000; Yeh et al., 1998). However, other observations seem to indicate 
that the extrinsic pathway per se is not essential for embryonic development but 
is part of a very complex mechanism that includes the enrollment of several 
pathways (Eimon et al., 2006). As a matter of fact, mice deficient for Fasl or 
Apo2L/TRAIL signaling complete embryogenesis(Cretney et al., 2002; Karray 
et al., 2004).  
Eimon and colleagues characterized the extrinsic pathway in zebrafish to 
determine how it operates in a non-mammalian vertebrate (Eimon et al., 2006). 
They identified the zebrafish homologs of Fasl and Apo2L/TRAIL, their 
receptors, and other components of the cell death machinery. Studies with three 
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Apo2L/TRAIL homologs demonstrated that they bind the receptors hdr 
(previously linked to hematopoiesis) and ovarian TNFR (otr). Ectopic 
expression of these ligands during embryogenesis induced apoptosis in 
erythroblasts and notochord cells. Inhibition of hdr, otr, the adaptor fadd, or 
caspase-8-like proteases blocked ligand-induced apoptosis, as did antiapoptotic 
Bcl-2 family members. Thus, it was demonstrated that the extrinsic apoptosis 
pathway in zebrafish closely resembles its mammalian counterpart and 
cooperates with the intrinsic pathway to trigger tissue-specific apoptosis during 
embryogenesis (Eimon et al., 2006).  
The zebrafish fas and fasl genes are reported in the Ensembl database 
(http://www.ensembl.org/index.html). The annotation ENSDARG00000043586 
refers to fas, which is located on chromosome 17 of zebrafish, and the 
annotation ENSDARG00000011520 is relative to fasl, which is located on 
chromosome 20. fas encodes for a transcript of 984 bp, consisting of 8 exons 
and encodes a protein of 293 amino acids which has the 30% of amino acid 
identity with the human protein. The transcript of fasl is 1314 bp long, consists 
of 4 exons and encodes for a protein of 268 amino acids which has the 35% of 
amino acid identity with human FASL. For both fas and fasl proteins, the 
functional domains (TNFR and TNF respectively) are conserved. Both genes 
are not duplicated in the zebrafish genome and are therefore present in a single 
copy. 
Given this evidence, Fas and Fasl were involved in the regression of notochord 
cells in the nucleus pulposus of the adult rat and apoptosis has been 
demonstrated to be involved in the development of the Xenopus laevis 
notochord. But so far no functional studies have been performed in order to 
study the possible role directly played by fas/fasl in the notochord development 
and/or regression. Therefore, it should be useful to develop an in vivo model for 
the functional study of fas/fasl in this structure. 
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Classical chordoma is characterized by differentiated physaliferous cells typical 
of notochord tissue. Both the origin and the histological features of chordoma 
lead to hypothesize that one or more notochord regression steps can be affected 
during development in a few cells that would give rise to the tumor. The 
notochord cells remnants, living in a non-physiological environment might be 
subject to anomalous cellular signalling that would lead to a deregulation of 
programmed cell death, and although chordoma cells show a differentiated 
phenotype, they could proliferate out of control. Recently the T gene has been 
implicated in the pathogenesis of chordoma and so far, its expression has an 
important significance as diagnostic hallmark of chordoma. However, the 
genetic basis of T expression in chordoma is largely unknown as only somatic 
copy-number changes of T gene have been observed in a minority of cases, 
including minor allelic gain in 4.5% of cases and amplification in 7% of cases. 
In addition no mutation of T have been detected. Therefore, the question of how 
Brachyury orchestrates chordoma development remained open. The finding of 
the T expression in this tumor might be due to its deregulated expression in 
notochord cells, alternatively the defects in notochord regression may maintain 
proliferating notochord cells which express the T gene, or both of these 
possibilities. Therefore, studies of T expression regulation are necessary to 
clarify chordoma tumorigenesis, but also parallel studies aimed at identifying 
further mechanisms involved in the biology of this tumor and in the notochord 
development/regression should be pursued, performing functional studies in 
suitable animal models. 
Interestingly, it has been reported that the proper balance between notochord 
cell proliferation and apoptosis is fundamental for the development and 
regression of the notochord. Accordingly, the apoptotic process is involved in 
normal notochord development in Xenopus laevis, and in particular the extrinsic 
apoptotic pathway is necessary for notochord development in zebrafish. In 
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addition the expression of the tumor necrosis factor receptor (TNFR) Fas and its 
ligand (TNF) Fasl, activating the extrinsic apoptosis, leads to the notochordal 
cells regression in the intervertebral disks of the adult rat. The autocrine-
paracrine interaction between Fas and Fasl, resulting in the trimerization and 
activation of the Fas receptor, leads to cell death. Besides their role in 
apoptosis, these factors have also been implicated in survival/proliferation and 
cell cycle progression showing a tumor suppressor activity. Multiple 
mechanisms regulate the sensitivity of Fas-expressing cells to Fas-induced 
apoptosis, including alternative splicing of FAS pre-mRNA: mRNAs lacking 
exon 6 encode soluble form of the receptor, which, sequestering Fasl, lead to a 
reduction of Fas signaling, inhibiting apoptosis.  
On the basis of the above premises, the first aim of my PhD project was to 
investigate the FAS/FASL pathway activity in SBC specimens, obtained thanks 
to the collaboration with the Dipartimento di Neurochirurgia of the Ospedale 
San Raffaele, Milan. I studied FAS and FASL gene and protein expression in 34 
SBCs and the presence of alternative-spliced forms of FAS in a subgroup of 12 
SBC. To investigate the activation status of Fas/Fasl pathway in chordoma 
tumors we also verified the activation of downstream caspases 3 and 8. 
Since failure of apoptosis is known to be a key mechanism for the induction and 
maintenance of the neoplastic phenotype, we hypothesized that apoptosis might 
be deregulated also in chordoma. In order to investigate whether apoptotic 
processes can be enhanced in chordoma cell lines inducing their regression, a 
further aim of my project was to administrate soluble Fasl to the chordoma cell 
line U-CH1 and then study the Fas apoptotic pathway activity. At this purpose, 
the U-CH1 cells were exposed to soluble Fasl at different doses and times. 
These experiments were performed in collaboration with Prof. Canti, Dip. 
Biotecnologie Mediche e Medicina Traslazionale. The increase of Fas/Fasl 
pathway activation would pinpoint Fasl as a potential therapeutical molecule to 
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be evaluated in further pharmacological studies and Fas as a pharmacological 
target.  
With the aim of identifying the molecular mechanisms leading to chordoma, we 
carried out in vivo functional studies on notochord development interfering with 
fas/fasl expression in zebrafish animal model. These experiments were 
performed in collaboration with Prof. Franco Cotelli, Dip. Bioscienze, 
Università degli Studi di Milano. 
Thus, we firstly evaluated the expression of fas and fasl in the zebrafish whole 
embryos and larvae and in the notochord. Then we performed the loss-of-
function experiments by using morpholino technology, in order to analyze 
notochord defects in zebrafish embryos and larvae, which were characterized by 
both histological and molecular techniques, also considering the expression of 
ntla and col2a1a genes, which were found to be deregulated in chordoma. The 
purpose of this study, besides providing new insights on notochord biology, 
was to identify new pathogenetic mechanisms underlying chordoma 
tumorigenesis.  
Zebrafish as a developmental model system 
Zebrafish (Danio rerio) is a tropical fish native to Southeast Asia. It possesses a 
unique combination of features that makes it particularly well suited for 
experimental and genetic analysis of early vertebrate development. Zebrafish 
adults are small, so many fishes can be housed in a small space. They have a 
relatively short generation time, an adult female reaches the sexual maturity in 
about three months and it lays hundreds of eggs per mating every few weeks, 
generating many progeny for genetic or experimental analysis. The zebrafish 
eggs are fertilized and develop externally to the mother, providing ready access 
to the developing animal at all stages of its development. The fertilized 
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embryos develop rapidly, making it possible to observe the entire course of 
early development in a short time. Somitogenesis begins at about 9 hpf and at 
24 hpf the zebrafish embryo has already formed all the major tissues and many 
organ precursors, such as a beating heart, circulating blood, nervous system, 
eyes and ears, all of which can be readily observed under a simple dissecting 
microscope. Larvae hatch by about 2.5 dpf and they are swimming and feeding 
by 5–6 dpf (Weinstein, 2002). A variety of tools and methodologies have been 
developed to exploit the advantages of the zebrafish system. Zebrafish embryos 
and early larvae are optically clear, allowing for direct, non-invasive 
observation or experimental manipulation at all stages of their development 
such as Whole-mount In Situ Hybridisation (WISH) analysis of gene expression 
patterns with extraordinarily high resolution (Vogel and Weinstein, 2000). The 
externally developing embryos are readily accessible to experimental 
manipulation by techniques such as microinjection of biologically active 
molecules (RNA, DNA or antisense oligonucleotides), cell transplantation, fate 
mapping and cell lineage tracing (Holder and Xu, 1999; Kozlowski and 
Weinberg, 2000; Mizuno et al., 1999; Reifers et al., 2000a; Reifers et al., 
2000b). The genetic methods available in the fish have been complemented in 
the last few years by a full array of genomic and molecular genetic tools. 
Relatively dense meiotic and radiation hybrid maps now allow for the rapid 
genetic and physical localization of mutations and genes 
(http://zfish.uoregon.edu). Large-insert clones of genomic DNA are available 
from Yeast Artificial Chromosome (YAC), Bacterial Artificial Chromosome 
(BAC) and P1 Artificial Chromosome (PAC) libraries. Extensive Expressed 
Sequence Tag (EST) sequencing and mapping projects are underway 
(http://zfish.wustl.edu). Efforts have also been initiated to obtain the complete 
sequence of the zebrafish genome, a feat that will undoubtedly dramatically 
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increase the usefulness of the mutants and genetic tools available in the fish 
(Vogel and Weinstein, 2000). 
 
 
Project aims 
Starting from the reported rationale, my PhD project was outlined in two 
different principal objectives: 
• to analyze the activity of Fas/Fasl pathway in skull base chordoma and 
study whether the apoptotic processes can be enhanced in the U-CH1 
chordoma cell line by the exposure to soluble Fasl 
•  to study the functional role of fas and fasl in the in vivo zebrafish 
(Danio rerio) model in order to investigate their possible implication in 
notochord development, differentiation and regression and thus helping 
to unravel mechanisms possibly involved in chordoma onset  
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Fas/Fasl pathway impairment in skull base chordoma addresses 
identification of potential pharmacological targets  
The first aim of my PhD project was to investigate the FAS/FASL pathway 
activity in skull base chordomas. At this purpose, we studied FAS and FASL 
gene expression in tumors from a cohort of 34 SBC samples and in the U-CH1 
chordoma cell line by RT-PCR. Most of the analyzed samples showed FAS 
expression, while in 62% of them FASL transcript was not detected. Otherwise 
the U-CH1 cell line expressed both genes, as well as in the control tissue 
Nucleus Pulposus (NP). To investigate the activation status of this pathway in 
chordoma tumors and U-CH1 cells, we checked for the expression of the pro-
apoptotic and anti-apoptotic FAS isoforms. This latter study was performed in a 
sub-group of twelve tumors because of the paucity of the biological material. 
All the chordoma samples and the U-CH1 cell line showed the expression of 
both transmembrane and soluble FAS, while NP showed exclusively the 
expression of the pro-apoptotic transmembrane isoform.  
In order to identify mechanisms possibly causing FAS/FASL expression 
deregulation, we genotyped our SBC patients for the presence of specific 
functional SNPs that have been reported to be correlated to differential allelic 
FAS and FASL expression in different tumors. The finding of the G/G FAS 
rs2234767 genotype in all chordoma patients, associated to high FAS 
expression levels, suggests that there would not be constitutional FAS 
expression reduction. Similarly, the C/C FASL rs763110 genotype has been 
associated to higher FASL expression level than T/T or T/C genotypes, thus 
these results did not allow to correlate FASL dysregulation in SBC to any of 
FASL rs763110 genotypes. Despite the low number of chordoma analyzed, this 
evidence let us to hypothesize that these functional SNPs are not directly 
associated to the observed expression dysregulation of FAS/FASL in SBCs, 
differently from what was previously reported for other type of tumors. 
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Therefore, other mechanisms could play a role in the control of FAS and FASL 
expression. We speculated that methylation and/or both post-transcriptional 
expression modulation by specific miRNAs might affect FASL expression 
regulation. Furthermore, the alternative splicing deregulation of FAS, enhancing 
the expression of anti-apoptotic isoform in chordoma, might be caused by the 
altered expression of one or more specific splicing factors known to be involved 
in FAS splicing. 
This evidence led us to speculate that even when Fasl is expressed in SBCs, it 
poorly interacts with its transmembrane receptor for the presence of the soluble 
Fas which, acting as competitor, maintains inactivated the Fas/Fasl mediated 
pro-apoptotic signaling. All these results suggest that the activation status of 
Fas/Fasl pathway is impaired in chordoma. 
In order to confirm our hypothesis on the impairment of Fas/Fasl pathway in 
SBC, we studied the presence of the activated downstream effectors Caspase 8 
and Caspase 3 in the sub-group of 12 SBC samples by western blot. The 
inactive Caspase 8 was found to be expressed in all the samples analyzed, while 
the active form, a cleaved product derived from the Caspase 8 activation, was 
found to be weakly expressed only in three tumors. As far as the Caspase 3, the 
only inactive form was detected. These findings strongly support our hypothesis 
on the impairment of Fas/Fasl apoptotic pathway in chordoma. Therefore, this 
evidence led us to hypothesize that the exposure of chordoma cell line to 
soluble Fasl (SuperFAS Ligand) might strengthen the activation of apoptosis 
mediated by the transmembrane Fas, competing with the Fas anti-apoptotic 
soluble isoform.  
At this purpose we studied whether the administration of soluble Fasl may 
increase the Fas apoptotic pathway activity in the U-CH1 chordoma cell line. 
The U-CH1 cells were exposed to soluble Fasl at different doses and times. We 
observed a significant induction of the apoptosis in the treated cells by means of 
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cytofluorimetric apoptotic assays, besides the significant increase of Pre 
caspase 8 together with the significant decrease of Pro caspase 8 levels in a 
dose and time exposure dependent manner. These data confirm our hypothesis 
and indicate that Fas pathway activity can be increased in this tumor.  
The evidence obtained led us to speculate that Fas may be a potential 
therapeutic target and Fasl a potential pharmacological molecule, addressing 
studies aimed at identifying effective chemotherapeutical protocols for the 
treatment of chordoma. 
 
fas/fasl downregulation impairs zebrafish notochord 
morphogenesis and regression affecting the expression of 
specific chordoma markers 
Chordoma originates from notochord remnants that do not disappear during 
development of vertebral bodies. The apoptotic mechanisms are fundamental 
for notochord cells development and regression. Accordingly, the Fas/Fasl 
pathway was found to be involved in specific notochordal cells’ regression step. 
Since we found that the FAS/FASL expression is dysregulated in chordoma and 
the pathway was found to be inactivated, we thus hypothesized that Fas/Fasl 
pathway dysregulation may have a role in chordoma onset. To unravel this 
issue we investigated the function of fas and fasl homologs in the zebrafish 
animal model notochord development. These genes are evolutionary conserved 
from fish to mammals. We firstly evaluated the expression of fas and fasl in the 
zebrafish whole embryos and larvae by RT-PCR. While fas was maternally and 
zigotycally expressed, fasl showed a maternal expression and a zygotic 
expression starting from 24 hpf. The expression pattern of fas and fasl in brain, 
eyes, gut, ovary of the adult fish is conserved in mammals, supporting the 
conservation of FAS/FASL function during evolution.  The detection of fas and 
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fasl expression in zebrafish notochord sorted cells at the first stages of 
development, pinpoints for the first time the involvement of these two genes in 
the processes of notochord formation. Morpholino mediated knock-down of fas 
and fasl caused specific aberrant phenotypes such as bent tails and motility 
defects. Morphological and histological analyses of the fas/fasl morpholino-
injected embryos and larvae showed notochord multi-cell-layer jumps instead 
of the typical “stack-of-coins” organization, larger notochord vacuolated cells, 
defects in the peri-notochordal sheath structure and in vertebral mineralization. 
It is known that these alterations are determined by notochord differentiation 
impairment. Interestingly, the defects in notochord differentiation following 
fas/fasl loss-of function, closely correlate with the phenotypes observed after 
the deregulation of other genes expressed in the notochord or in the 
perinotochord sheath, such as col15a1, col27a1a and col27a1b.  
In addition, the loss-of-function of fas/fasl produced disorganized myofibrils 
and an aberrant primary motoneurons branching, resulting in a motility 
impairment. Indeed, both muscles and motoneurons formation require proper 
signaling from the notochord, and it has been demonstrated that also the 
integrity of the perinotochordal sheath is essential for the axon projections. 
The knockdown of fas and fasl resulted later during development in vertebrae 
mineralization defects instead of the normal notochord ossification. Therefore, 
fas/fasl loss-of function might alter the proper notochord cells disappearance 
during notochord regression, similarly to what happens to the notochord cells in 
the nucleus pulposus of rat. This might cause the mechanical weakening of 
notochord sheath leading to defects in vertebrae formation. 
To investigate whether the notochord aberrant phenotypes, observed in fas/fasl 
loss-of-function zebrafish, showed molecular alteration common to chordoma, 
we studied the expression of two chordoma markers' homologs, ntla (T) and 
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col2a1a (COL2A1), that are also finely regulated during notochord 
development and differentiation. 
These two genes were found significantly upregulated and their expression was 
maintained in fas/fasl-MO-injected embryos in a developmental stage in which, 
in controls, they normally diminished and disappeared. These results are in 
accord with data on the reported hyper-expression of the homologs T and 
COL2A1 genes in chordoma. 
The obtained results allowed us to demonstrate that fas/fasl are involved in 
proper notochord development, differentiation and regression in zebrafish, and 
the effects detected by their deregulation are consistent with the implication of 
FAS/FASL pathway defects in chordoma onset.  
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Conclusions and Perspectives 
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Conclusions 
• Dysregulaton of FAS/FASL in most SBCs analyzed, presence of both 
pro- and anti-apoptotic FAS isoforms and detection of the prevalent 
expression of inactive forms of both Caspase- 8 and Caspase- 3 SBCs 
analyzed 
• FAS/FASL functional SNPs are not directly associated to the expression 
dysregulation of these genes in SBCs analyzed 
• Significant induction of the apoptosis in the U-CH1 chordoma cells 
following treatment with soluble Fasl indicate that this pathway can be 
activated in chordoma 
• fas and fasl zebrafish homologs were specifically expressed in the 
notochord 
• Morpholino mediated knock-down of fas and fasl caused specific 
aberrant phenotypes such as bent tails and motility defects, notochord 
multi-cell-layer jumps instead of the typical “stack-of-coins” 
organization, larger notochord vacuolated cells, defects in the peri-
notochordal sheath structure and in vertebral mineralization 
• The two chordoma markers ntla (T) and col2a1a (COL2A1), were found 
to be deregulated in fas/fasl morpholino-injected embryos 
 
• Fas/Fasl pathway activity can be enhanced in chordoma. Moreover, fas 
and fasl are involved in in notochord development, differentiation and 
regression in zebrafish suggesting the implication of this pathway in 
chordoma onset 
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Perspectives 
• to investigate genetic/epigenetic mechanisms possibly involved in FASL 
silencing or down regulation 
• to study the mechanisms leading to FAS antiapoptotic isoform 
overexpression in chordomas, in U-CH1 chordoma cell line 
 
• to interfere with FAS different isoforms expression in U-CH1 cell line  to 
study the possible different induction of apoptosis following soluble Fasl 
treatments 
 
• to identify drugs that in combination with soluble Fasl treatment are able to 
induce apoptosis and inhibit growth in chordoma cell lines 
 
• to generate fas and fasl zebrafish conditional mutants to better understand 
their implication in notochord development/regression at specific 
developmental stages and to investigate their potential causative role in 
tumorigenesis processes 
• to generate xenotransplantation of human chordoma U-CH1 cells in 
zebrafish embryos to study the potential of tumor cells invasiveness and 
metastasis and to assess in vivo anticancer therapies 
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fas/fasl downregulation impairs zebrafish notochord formation affecting the 
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Abstract 
The chordoma is a malignant tumor characterized by chemoresistance and unforeseeable prognosis. 
This tumor originates from notochord remnants that do not disappear during development of 
vertebral bodies. The apoptotic mechanisms are fundamental for notochord cells development and 
regression. accordingly the Fas/Fasl pathway was found to be involved in specific notochordal 
cells’ regression steps. Interestingly FAS/FASL expression is dysregulated in chordoma and the 
pathway was found to be inactivated. We thus hypothesized that Fas/Fasl pathway dysregulation 
may have a role in chordoma onset. To unravel this issue we investigated the function of fas and 
fasl homologs in the zebrafish notochord development. We found that these genes were 
evolutionary conserved from fish to mammals and were specifically expressed in notochord cells. 
Morpholino mediated knock-down of fas and fasl resulted in abnormal phenotypes mainly showing 
curved tail and altered motility. Notochord multi-cell-layer jumps instead of the typical “stack-of-
coins” organization, larger vacuolated cells, defects in the peri-notochordal sheath structure and in 
vertebral mineralization have been detected in most morphants. In addition, we observed the 
persistent expression of ntla and col2a1a, the zebrafish homologs of the human T gene and 
COL2A1, which were found to be specifically upregulated in chordoma. These data demonstrate the 
role of fas and fasl in notochord development, differentiation and regression in zebrafish suggesting 
the implication of this pathway in chordoma onset. 
 
Introduction 
Chordoma is a rare slow-growing malignant bone tumour arising from embryonic remnants of the 
notochord that do not disappear during development of vertebral bodies. This tumour is 
characterized by local invasiveness and variable tendency for recurrences. Metastases are rare and 
are more likely to be confined to terminal stages of disease. Chordomas can localize at skull base, 
sacral or spinal axis level, and account for approximately 0.1%– 0.25% of intracranial tumors and 
1% - 4% of all malignant bone tumors (1, 2). The treatment of choice for these tumors is en-bloc 
resection followed by postoperative radiation therapy (3). To date chordoma is considered 
unresponsive to chemotherapy and no validated molecular markers are available to monitor the 
tumor progression (3). 
The maintenance of the notochordal tissue characteristics in chordoma is confirmed by microscopic 
features, the localization of the tumor along the axial skeleton, and the expression of similar 
transcription factors. Among them, the most significant is the transcription factor T (encoding for 
Brachyury),  the founder member of the T-box family involved in notochord development (4-6) and 
recently identified as the pathognomonic marker for chordoma. Brachyury is predicted to be a 
master regulator of an elaborate oncogenic transcriptional network encompassing diverse signalling 
pathways including components of the cell cycle and extracellular matrix components. The 
evidence of duplication of the 6q27 region, including the T gene, indicates the involvement of this 
transcription factor or its specific target genes in the tumor onset. At a functional level, the silencing 
of Brachyury induced growth arrest in a chordoma cell line (7, 8), while its overexpression, 
observed in the human pancreatic cell line PANC-1 which does not express it, resulted in enhanced 
proliferation, motility and invasiveness (9). In a recent characterization of chordoma tumors and 
cell lines, other genes were found differentially expressed; among them the α1 collagen type II 
(COL2A1) was significantly overexpressed (10). 
The proper balance between notochordal cell proliferation and apoptosis seems to be fundamental 
for the development and regression of the notochord. The apoptotic process is involved in normal 
notochord development in Xenopus laevis (11), and in particular the extrinsic apoptotic pathway is 
necessary for notochord development in zebrafish (12). In addition the expression of tumor necrosis 
factors (TNFs) FAS and its ligand FASL, activating the extrinsic apoptosis, leads to the notochordal 
cells regression in the adult rat intervertebral disks (13, 14).  
Our recent findings demonstrated that FAS and FASL expression is dysregulated in skull base 
chordoma and in the U-CH1 chordoma cell line mainly for the coexpression of the anti-apoptotic 
and pro-apoptotic FAS isoforms and the lack of FASL transcript that leads to apoptosis impairment   
(Ferrari et al., 2013 under revision). 
In view of the chordoma arise from notochordal remnants that could remain following misleading 
apoptotic events, we sought to turn to the zebrafish (Danio rerio) model to study the functional role 
of fas and fasl in the notochord development, differentiation and regression. 
The zebrafish notochord starts to form during gastrulation (15) when the antecedent of the 
notochord, the chordamesoderm, expresses brachyury (ntl) (16) sonic-hedgehog shh, and later α1-
collagen Type II (col2a1) (17). During the segmentation period of development, central cells of the 
notochord differentiate and acquire a large vacuole and the notochord becomes surrounded by a 
sheath of tissue, which in combination with the turgor pressure, generated by the vacuolated cells, 
imparts to the notochord its stiffness (18). The differentiation correlates to apoptotic events that in 
the zebrafish notochord and peri-notochoral sheath happen between 14 and 24 hours post 
fertilization (hpf) of development (19). As notochord cells become vacuolated, the expression of ntl, 
shh and col2a1 are each extinguished in the notochord (16) while expression of shh is maintained in 
the floor plate and col2a1 in the floor plate and the hypochord (17, 20).  
Members of the extrinsic apoptotic pathway have been identified in teleosts and they closely 
resemble their mammalian counterpart (21): studies with the Apo2 ligand/tumor necrosis factor 
related apoptosis-inducing ligand (Apo2L/TRAIL) homologs demonstrated that they induced 
apoptosis in erythroblasts and notochord cells and fas and fasl homologs have been identified on 
chromosome 17 and 20 respectively with conserved synteny between fish and mammals (12). In the 
present study, we found that fas/fasl are expressed in notochord cells and are required for notochord 
differentiation and regression. Indeed, simultaneous knock-down of fas and fasl resulted in 
notochord multi-cell-layer jumps instead of the typical “stack-of-coins” organization, larger 
vacuolated cells, defects in the peri-notochordal sheath structure and in vertebral mineralization. 
Interestingly, we also observed the maintenance of the oxpression of ntla and col2a1a, the zebrafish 
homologs of the human T gene and COL2A1, which were found to be specifically upregulated in 
chordoma (10). This data suggest the implication of fas/fasl pathway in chordoma tumorigenesis. 
 
Material and methods 
Animals 
Breeding wild type fish of the AB strain were maintained at 28°C on a 14 h light/10 h dark cycle. 
Embryos were collected by natural spawning, staged according to Kimmel and colleagues (15) and 
raised at 28°C in fish water (Instant Ocean, 0,1% Methylene Blue) in Petri dishes, according to 
established techniques, approved by the veterinarian (OVSAC) and the animal use committee 
(IACUC) at the University of Oregon, in agreement with local and national sanitary regulations. We 
express the embryonic ages in somites (s), hours post fertilization (hpf) and days post fertilization 
(dpf).  
The twhh-GFP construct was kindly provided by J. Du (22) and injected at a concentration of 200 
pg/embryo. 
The following line were used: AB obtained from the Wilson lab, University College London, 
London, United Kingdom, the ET30:Et(kita:GalTA4,UAS:mCherry)hzm line was kindly provided 
by R. W. Koster and M. Mione (23, 24), IFOM, Milan Italy, and Tg(flk1:EGFP) obtained from the 
Lawson lab, University of Massachusetts Medical School, Boston, USA. 
In situ hybridization, histological analysis and immunohistochemistry Whole mount in situ 
hybridization (WISH) experiments, were carried out as described by Thisse and colleagues (25). 
Antisense riboprobes were previously in vitro labelled with modified nucleotides (i.e. digoxigenin, 
fluorescein, Roche).  
For histological sections, stained embryos/larvae were re-fixed in 4% PFA, dehydrated and stored 
in methanol, wax embedded and sectioned (5-8 µm). col2a1a probe has been kindly provided by 
Topczewski laboratory and ntla probe was cloned already reported (26). 
RT-PCR 
Total RNA from 17 samples (an average of 30 embryos/larvae per sample) was extracted with the 
TOTALLY RNA isolation kit (Ambion, Life Technologies, Paisley UK), treated with RQ1 RNase-
Free DNase (Promega, Madison, WI) and oligo(dT)-reverse transcribed using SuperScript II RT 
(Life Technologies), according to manufacturers’ instructions. Following primers have been used: 
fas sense 5’-GTGACGCTAATGCAAAAATGAAG-3’ 
fas antisense 5’-CGATGTCCTGCAGAGTGGTG-3’ 
fasl sense 5’-CACTCGTCCCAACCAGTGGTTC-3’ 
fasl antisense 5’-AAGCTGGCAGATTGCATTG-3’ 
beta-actin sense 5'-TGTTTTCCCCTCCATTGTTGG-3';  
beta-actin antisense 5'-TTCTCCTTGATGTCACGGAC-3'; 
 
Quantitative real time RT-PCR 
Reverse transcriptions (RTs) were performed using 2 µg of DNase treated (DNA-free™, Ambion) 
total RNA in presence of random hexamers (Life Technologies) and SuperScript II reverse 
transcriptase (Life Technologies). Real-time PCRs were carried out in a total volume of 15 µl 
containing 1X iQ SYBR Green Super Mix (BioRad, Barckley, CA), using 1 µl of the RT reaction. 
PCRs were performed using the BioRad iCycler iQ Real Time Detection System (BioRad). For 
normalization purposes, ef1-alpha RNA level was tested in parallel with the gene of interest. The 
following primers were used:  
ntla_sense 5’-CCTCGGGTTCGTACTGTGAG-3’ 
ntla_antisense 5’-TCCGGAAGAGTTGTCCATGT-3’ 
col2a1a_sense 5’-ATCCCATCATTTCACCTGGA-3’ 
col2a1a_antisense 5’-TCTGTCCCTTTGCACCAAGT-3’ 
ef1alpha_sense 5’-GGTACTTCTCAGGCTGACTGT-3’;  
ef1alpha_antisense 5’-CAGACTTGACCTCAGTGGTTA-3’. 
 
Injections Injections were carried out on 1- to 2-cell stage embryos; the dye tracer rhodamine 
dextran was also co-injected. To repress fasl and fas mRNA translation, an ATG-targeting 
morpholino (fas-MO, fasl-MO) and a splice-MO were synthesized (splice-fas-MO, splice-fasl-MO) 
(Gene Tools LLC, Philomath, OR):  
fas i1e2 5’-TCCTGTAATACACAAACACATGCAG-3’  
fasl e1i1 5’-TACATTCTGTAGGTCTTACCTGTGT-3’  
fas ATG 5’-TCGAGGAGGTCACCCGAATTAGA-3’  
fasl ATG 5’-GGCCGAAGTTAGCACTCATGTTTGC-3’  
and used at the concentration of 0,5 pmol/embryo in 1x Danieau buffer (pH 7,6) as previously 
reported (27). As control we injected a standard control morpholino oligonucleotide (ctrl-MO). The 
in-vivo test of the specificity was carried out as described in Brusegan and colleagues (28). In brief: 
200 pg/embryo of the pCS2+-fasl-MO-EGFP sensor plasmid have been injected alone or co-
injected with 0,5 pmol/embryo of fasl-MO. The presence/absence of the GFP signal has been 
monitored under a fluorescent microscope from 24 to 48 hpf. fasl-MO cDNA fragments inserted in 
the BamHI site were obtained using the following complementary oligos:  
sense 5’-gatcGATCGCAAAACATGAGTGCTAACTTCGGCC-3’; 
antisense 5’-gatcGGCCGAAGTTAGCACTCATGTTTGC-3’; 
Same results were obtained with the pCS2+-fas-MO-EGFP.  fas-MO cDNA fragments inserted in 
the BamHI site were obtained using the following complementary oligos:  
sense 5’-gatcTCTAATTCGGGTGACCTCCTCGA- 3’ 
antisense 5’-gatcTCGAGGAGGTCACCCGAAT-3’ 
 For the specificity of phenotype, 0,7 pmol of fasl-MO was injected together with 200 pg/embryo of 
endogenous fasl full length mRNA. Synthetic capped fasl mRNA was obtained using the following 
primers: 
fasl_sense 5’-TTTGAATTCCGCCACCATGAGTGCTAACTT-3’; 
fasl_antisense 5’-TTTGCTCTAGAGATCAGTGGATCTTAAAGA-3’; 
cloned into the PCS2+-expression-vector and transcribed with the mMessage kit (Ambion).  
To validate splice-site-MO (splice-fas-MO and splice-fasl-MO) and verify intron retention or exon 
skipping respectively, following primers were used: 
fas exon 1_sense 5’-ATGCCCACTTTGACTTATAGC-3’; 
fas exon 7_antisense 5’-GATGAAGCCTCGACAATGTTC-3’; 
fasl exon 1_sense 5’-ATGAGTGCTAACTTCGGCCAC-3’; 
fas exon 4 reverse 5’-AAGCTGGCAGATTGCATTG-3’. 
 
Sorting 
50-100 twhh-GFP transgenic embryos at 24 and 48 hpf were incubated in trypsin solution (0.5% 
trypsin and 1mM EDTA) for 2 h with gentle pipetting to dissociate the cells. Cells were 
resuspended in PBS (Gibco, Life Technologies)-20% fetal calf serum (FCS; Euroclone, Milan, 
Italy)-20 mM HEPES and 2 mM EDTA and filtered through 40-µm cell strainers (Euroclone) 
before sorting using a Vantage Sorter SE (Becton-Dickinson, San Jose, CA) at a flow rate of 3000 
cells per second. GFP was exited at 488 nm using an argon laser. Cells dissociated from wild-type 
embryos were used to set the gating to exclude green autofluorescence. After sorting, the GFP+ 
cells were collected and RNA was extracted with the micro-RNAeasy kit (Qiagenm, Venlo, 
Netherlands). RNA was directly retro-transcribed with the iSCRIPTtm cDNA synthesis kit (Biorad) 
and the obtained cDNA was used for RT-PCR reactions.  
 Confocal images 
Live ET30 transgenic fish were anesthetized in a 0,5% tricaine solution in fish water, then mounted 
in a 1% low melt agarose. Embryos were imaged on a Leica TCS NT confocal microscope. 
 
Calcein staining 
Calcein (Sigma-Aldrich, Italy) staining was done according to Du and colleagues (22, 29). 
 
 
Results 
Zebrafish fas and fasl are expressed in notochordal cells 
The zebrafish orthologs of human FAS and FASL were identified in previous works (12, 21); they 
are present in a single copy in the genome and they conserve the architecture of the functional 
domains (12).  
We performed RT-PCR analyses of fas and fasl in the developing embryo, larva and in adult tissues 
(Fig. 1A). Interestingly, while fas is expressed in all the analyzed developmental stages, fasl 
expression is modulated during development. In fact, as shown in figure 1A, fasl presented a 
maternal expression while the zygotic expression started from 24 hpf. To specifically analyze the 
expression of fas and fasl in the notochord, we took advantage from the microinjection of the GFP-
construct twhh:GFP-pCS2+, in which the twhh promoter directs the GFP expression in notochord 
cells (29). We then FACS-sorted GFP positive cells from embryos at 24 and 48 hpf and analyzed 
fas and fasl expression by RT-PCR. As shown in figure 1B, fas is detected in the notochord cells at 
both 24 and 48 hpf while fasl only at 48 hpf. Studies previously reported, fas and fasl expression 
were not seen by whole-mount in situ hybridization (WISH) during the first stages of development 
(12). 
fas and fasl loss-of-function phenotypes 
To investigate the function of fas and fasl in zebrafish development, we employed the knock-down 
strategy using oligonucleotide-antisense morpholinos targeting the ATG start codon (fas-MO and 
fasl-MO respectively). Both morpholinos were injected at a concentration of 0,7 pmol/embryo or 
co-injected (fas/fasl-MO) at a concentration of 0,5 pmol/embryo each. The knock-down embryos 
were compared to embryos injected with the same amount of a non-specific control MO (ctrl-MO) 
at the same developmental stage.  
The embryos injected with the fas-MO showed a phenotype from 24 hpf while embryos injected 
with the fasl-MO showed no overt phenotype prior to 48 hpf, consistently with the temporal 
expression of zygotic fasl mRNA from 48 hpf (Fig.2A). Moreover, embryos co-injected with 
fas/fasl-MO at a dosage that did not individually cause morphological defects (0,5 pmol/embryo of 
fas-MO and 0,5 pmol/embryo of fasl-MO) presented the same phenotypical defects of the single 
fas- or fasl-MO injection. Therefore, for all the following results, we decided to show the double 
knock-down. The fas/fasl-loss of function phenotype was charactherized by bent notochord, curved 
tail and cephalic and cardiac edema (Fig. 2 B-D’) and was worsening during later stages of 
development. In addition, from 3 dpf, the most evident defect in fas/fasl-MO injected embryos was 
a high reduction in motility. The ctrl-MO injected larvae escaped in the opposite direction when 
stimulated (100% N=50, Movie 1), fas/fasl-MO injected larvae were characterized by an altered 
motility, swimming in circle (80% N=80, Movie 2). As explained above, the single or concurrent 
injection of fas and fasl morpholinos gave rise to the same phenotype. Following the injection of 
fasl mRNA and, we were able to rescue the phenotype, confirming the specificity of the 
downregulation (80% N=65 Movie 3). Moreover, we designed splice-site morpholinos (splice-fas-
MO and splice-fasl-MO) that presented consistent phenotypes with the ATG morpholinos, 
confirming the specificity of the loss-of-function.  
We tested the in-vivo efficiency of the ATG morpholinos, sensor plasmids containing the sequence 
targeted by fas (pCS2/fas-MO1-EGFP) and fasl morpholinos (pCS2/fasl-MO1-EGFP) in frame with 
the EGFP sequence, were co-injected with fas-MO, fasl-MO or ctrl-MO respectively (Suppl. Fig. 
S1). The presence/absence of the EGFP was monitored at 24 hpf. Most (80%, N=25) of the 
embryos injected with the sensor plasmid and the ctrl-MO were positive for the EGFP (Suppl. Fig. 
S1 A-A’). This percentage decreased to 15% (N=50) when the plasmids were co-injected with fas-
MO (Suppl. Fig. S1 B-B’) or fasl-MO (Suppl. Fig. S1 C-C’), indicating that morpholinos 
specifically bind to their target regions. Moreover, RT-PCR performed on the splice-site-
morpholinos targeted regions (splice-fas-MO and splice-fasl-MO), showed abnormal splicing in 
embryos injected with fas (Suppl. Fig. S1 D) and fasl respectively (Suppl. Fig. S1 E), and normal 
splicing in control-MO injected embryos.  
Notochord architecture and surrounding tissues are affected in fas/fasl-MO injected larvae 
Because fas and fasl are expressed in the notochord, we analyzed possible defects caused by 
fas/fasl-loss-of-function in this structure and in the surrounding tissues. Taking advantage of the 
ET30:Et(kita:GalTA4,UAS:mCherry)hzm (ET30) transgenic line, where the fluorescent protein 
mcherry is expressed in notochord cells (23, 24), we were able to analyze the morphology of the 
notochord. Notwithstanding the curved tails and the notochord bents observed in fas/fasl-MO 
injected embryos starting from 24 hpf, no evident morphological defects in the notochord cells were 
shown before 48 hpf (data not shown). However, later during development (i.e. 4 dpf) the fas/fasl-
MO injected larvae presented notochord undulations and multi-cell-layer jumps (Fig. 3B) instead of 
the single “stack-of-coins” structure which is characteristic of ctrl-MO injected larvae (Fig. 3A) .  
Moreover, longitudinal sections of fas/fasl-MO injected larvae at 4 dpf showed that the notochord 
cells and the entire notochord structure were bigger in comparison to ctrl-MO injected larvae and 
the lager vacuolated cells were not properly connected to the peri-notochordal sheath, indicative of 
a failure of the cells to differentiate (Fig. 3C-D). Indeed, the peri-notochordal basement membrane 
of fas/fasl-MO injected larvae at 4 dpf, was abnormally undulated and thicker than the ctrl-MO 
injected larvae, in particular in areas where the profile of the notochord is bent (Fig. 3C-D).  
We considered the possibility that the defects in notochord morphology might have resulted from a 
general developmental delay, although fas/fasl-loss-of-function embryos did not differ noticeably in 
overall development from control-MO. We then checked the vessels formation that was comparable 
in control and fas/fasl-MO flk1:EGFP-trangenic injected larvae (30) as shown in the Suppl. Fig. S2, 
indicating that they were at the same developmental stage. 
 
Muscle organization and primary motoneuron axonal projections are altered in fas/fasl-MO 
injected larvae 
The lack of motility of fas/fasl-MO injected larvae from 3 dpf, prompted us to analyze the muscle 
structure by means of histological sections: at 4 dpf fas/fasl-MO injected larvae showed muscles 
with a disorganized alignment of myofibrils that appeared undulated and oriented in unusual 
directions (Fig. 4A-B). To exclude that motility impairment could be due to motoneuron defects, we 
analyze primary motoneurons (visualized by the znp1 antibody). Primary motoneurons and their 
axon were formed in a proper number and position in fas/fasl-MO injected embryos at 24 hpf. 
However, the disorganization in muscle and myosepta caused a disorganized branching of axonal 
projections (Fig. 4C-D). 
 
Notochord defects in fas/fasl-MO injected larvae leads to abnormal vertebral development 
Several evidences suggest that the notochord has been directly implicated in the formation of 
vertebrae and intervertebral discs  (22, 31). Therefore, we verified whether defects in notochord 
differentiation and in fas/fasl-MO injected larvae could influence subsequent vertebral formation. 
We calcein stained fas/fasl-MO injected larvae at early (13 dpf, around 5 mm, Fig. 5A-B’) and 
complete vertebral mineralization (18 dpf, around 7-9 mm, Fig. 5C-D) and we showed that there 
were significant defects in vertebrae formation with extensive vertebrae fusion (15% N=30, Fig. 
5B,B’,D) in comparison to ctrl-MO injected larvae (0% N=30 Fig. 5A,A’,C).  
Expression of ntla and col2a1a in fas/fasl-MO-injected embryos is upregulated as in chordoma 
tumors. 
fas/fasl-loss-of-function resulted in alterations in notochord development, differentiation and 
regression and might model the morphological and molecular defects underlying the chordoma 
onset. Hence, we south to analyze the expression profile of the genes that have been found altered 
in the chordoma tumors, such as the T gene and COL2A1.  Both the zebrafish homologs ntla and 
col2a1a were found to be significantly upregulated in fas/fasl-MO-injected-embryos by Q-PCR 
(Fig. 6A-B). These results were confirmed by WISH analyses. The expression of ntla, that normally 
progressively decays 20 hpf (around 20 somite stage), was maintained at high levels in fas/fasl-MO 
injected embryos (50% of fas/fasl-MO-injected, total N= 30)  (Fig. 6C-D). The expression of 
col2a1a, that normally diminished from 30 hpf and disappeared at 48 hpf (Yan et al., 1995; Dale 
and Topczewski, 2011), persisted in the peri-notochordal sheath in fas/fasl-MO injected embryos at 
48 hpf (70% of fas/fasl-MO-injected, total N= 60) (Fig. 6E-F).  
 
Discussion 
Chordoma is a rare malignant bone tumor arising from embryonic remnants of the notochord that 
do not correctly disappear during development of vertebral bodies. The notochord regression is 
regulated by several mechanisms, and among them, the apoptotic process was demonstrated to play 
a relevant role (11, 32, 33). In particular, the FAS/FASL pathway is implicated in the regression of 
the notochordal cells during adult nucleus pulposus formation in rat (13). Starting from this 
hypothesis, we previously demonstrated that this pathway was deregulated in chordomas and in the 
U-CH1 chordoma cell line, mainly for the lack of FASL expression and for the presence of the anti-
apoptotic isoform of FAS (Ferrari et al., 2013 under revision). However, the unrevealing of Fas/Fasl 
role in chordoma onset made it necessary to develop a suitable animal model, therefore we moved 
to the zebrafish.  
We firstly evaluated the expression of fas and fasl in the zebrafish whole embryos and larvae. While 
fas was maternally and zigotycally expressed, fasl showed a maternal expression and a zygotic 
expression starting from 24 hpf. The expression pattern of fas and fasl in brain, eyes, gut, ovary of 
the adult fish is conserved in mammals, supporting the conservation of FAS/FASL function during 
evolution(14, 34-37).  The detection of fas and fasl expression in zebrafish notochord sorted cells at 
the first stages of development, pinpoints for the first time the involvement of these two genes in the 
processes of notochord formation. By using morpholino technology, we performed the loss-of-
function experiments to analyze notochord defects in zebrafish embryos and larvae. The single or 
concurrent knock-down of fas and fasl resulted in the same phenotypes characterized by curved 
bodies and bent tails. The fasl-MO injected embryos showed aberrant phenotypes from 48 hpf, 
while the fas-MO and the fas/fasl co-injected embryos showed aberrant phenotypes from 24 hpf. It 
is known that Fasl is expressed in a limited number of cell types such as the notochord, the central 
nervous system or the skeletal muscle (38, 39) and its expression is finely regulated during 
development; conversely, Fas is expressed in a variety of cell types (14). Therefore, the finding that 
fas-MO-injected embryos showed aberrant phenotypes at a stage of development where we 
observed fasl expression in the whole embryo, but we did not detect its expression in the sorted 
notochord cells, led us to hypothesize that the receptor might be activated by paracrine interaction 
with fasl. In addition, in human, the Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) drives 
the autoactivation of Fas in absence of Fasl expression (40). So far, no similar mechanisms have 
been described in zebrafish but, eventually, fas might undergo to autoactivation even in the absence 
of fasl.  
Following fas/fasl loss-of-funtion in zebrafish, severe alterations of the notochord morphology were 
observed, with various degrees of packed cells that were larger and not properly connected to the 
perinotochordal sheath, which presented structural defects. It is known that these alterations are 
determined by notochord differentiation impairment (41). Indeed, in the normal development in 
zebrafish, at around 20 hpf chordamesoderm cells start to differentiate into mature notochord cells 
and begin to secrete the components driving to the correct formation of perinotochordal base 
membrane. This structure is crucial for the mechanical support of the notochord against its own 
hydrostatic pressure and for the maintenance of its classic rod-like structure (42-44). Interestingly, 
the defects in notochord differentiation following fas/fasl loss-of function, closely correlate with the 
phenotypes observed after the deregulation of other genes expressed in the notochord or in the 
perinotochord sheath, such as col15a1, col27a1a and col27a1b (42, 43). 
In addition, the loss-of-function of fas/fasl produced disorganized myofibrils and an aberrant 
primary motoneurons branching, resulting in a motility impairment. Indeed, both muscle and 
motoneuron formation require proper signaling from the notochord, and it has been demonstrated 
that also the integrity of the perinotochordal sheath is essential for the axon projections (43, 45-47).  
Early depletion of fas and fasl, later resulted in vertebrae mineralization defects instead of the 
normal notochord ossification (26). fas/fasl loss-of function might alter the proper notochord cells 
disappearance during notochord regression, similarly to what happens to the notochord cells in the 
nucleus pulposus of rat (13). This might cause the mechanical weakening of notochord sheath 
leading to defects in vertebrae formation (43). 
To investigate whether the notochord aberrant phenotypes, observed in fas/fasl loss-of-function 
zebrafish, showed molecular alteration common to chordoma, we studied the expression of two 
chordoma markers' homologs, ntla (T) and col2a1a (COL2A1) (10), that are also finely regulated 
during notochord development and differentiation. These two genes were found significantly 
upregulated and their expression was maintained in fas/fasl-MO-injected embryos in a 
developmental stage in which, in controls, they normally diminished and disappeared, suggesting a 
role for fas/fasl in notochord development and differentiation. Conversely, Ntl-/- mice show the 
disorganisation of the notochord, and the ntla zebrafish mutants do not develop notochord and tail 
(48, 49). The expression of the human homologs of ntla, the T gene, terminates with notochord 
maturation even if it may be kept in a focal fashion during early childhood and sometimes 
throughout life. It is of interest that Brachyury (encoded by T gene), is expressed in a reduced 
number of low-grade malignant differentiated embryogenetic tumors, such as the chordoma tumor, 
so that it has been recently proposed as the ultimate solution to the differential diagnosis between 
chordoma and other tumors with similar characteristics (1, 2, 50). However, the genetic basis of T 
expression in chordoma is largely unknown as only somatic copy-number changes of T gene have 
been observed in a minority of cases (51), including minor allelic gain in 4.5% of cases and 
amplification in 7% of cases (7). In addition no mutations of T have been detected (52, 53). 
Therefore, the question of how brachyury orchestrates chordoma development remained open (50). 
On the other hand, COL2A1 is another gene previously found overexpressed in chordoma tumours 
compared with non-chordoma mesenchymal tumors, normal tissues, and intervertebral disks (10). 
Moreover, the upregulation of the col2a1a is linked to defects of the notochord sheath and of 
proteins’ aggregation in zebrafish notochord cells, as demonstrated in previous works (54, 55). The 
role of col2a1 in notochord remodelling is confirmed also in other models, such as in mouse, but its 
function is controversial in fact, Col2a1-null mice are enable to dismantle the notochord (56). 
Taking in account the above evidence, the results here provided, and considering that FAS/FASL 
pathway was recently found to be impaired in chordoma tumours and in UCH1 chordoma cell lines 
(Ferrari et al. 2013, under revision) we propose that the deregulated expression of FAS and/or FASL 
might alter the maturation, differentiation and regression of notochord cells. Thus, the remnant 
notochordal cells might be exposed to anomalous cellular signalling, leading to a deregulation of 
programmed cell death and a proliferation out of control. As a matter of fact, the upregulation of T 
gene leads to notochord cells proliferation (5, 9); alternatively the defects in notochord regression 
may maintain proliferating notochord cells expressing the T gene, or both these possibilities (50).  
This study, besides providing new insights on notochord biology, allowed us to infer new 
pathogenetic models underlying chordoma tumorigenesis, addressing future investigations.  
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 Figures 
 
 
Fig. 1 Expression analysis of fas and fasl. (A) RT-PCR performed on different developmental 
stages and adult tissues. fas is expressed in all the analyzed developmental stages, fasl presents a 
maternal expression, while the zygotic expression starts from 24 hpf. Both genes are expressed in 
all the adult tissues analyzed. (B) RT-PCR performed on cDNA of the notochord cells sorted from 
embryos at 24 and 48 hpf injected with the twhh:gfp plasmid. fas is expressed in the notochord cells 
at both 24 and 48 hpf while fasl only at 48 hpf.  
 
 Fig. 2 fas/fasl-loss-of-function phenotypes. (A) MO-injected embryos were analyzed by scoring 
the presence/absence of curved bodies and subdivided  into phenotypic classes.  (B-E) Embryos and 
larvae injected with ctrl-MO exhibit normal development at 24 hpf (B), 48 hpf (C), 3 dpf (D) and 5 
dpf (E). (A’-E’) Embryos and larvae co-injected with fas/fasl-MO develop defects in the tail 
curvature due to notochord distortion and cardiac edema. This phenotype is worsening during 
development.  
 
 
 Fig. 3 The lack of fas and fasl affects notochord differentiation and peri-notochordal sheath 
integrity. (A-B) Confocal images of the mcherry-positive-notochord cells of the ET30 transgenic 
line at 4 dpf. In ctrl-MO injected larvae (A), the notochord shows its characteristic “stack-of-coins” 
structure while fas/fasl-MO injected larvae (B) present notochord undulations and form multi-cell-
layer jumps. (C-D) Longitudinal sections hematoxilin-eosin (HE) stained of ctrl-MO and fas/fasl-
MO injected larvae at 4 dpf. The notochord (n) of morphants is thicker, and vacuolated cells are not 
properly connected to the peri-notochordal sheat that is abnormally undulated (arrowheads, D), in 
comparison to ctrl-MO injected larvae (C). (A-D) lateral views, anterior to the left, dorsal up. Scale 
bars: 100 µm. 
 Fig. 4 Defects in notochord differentiation prevent normal muscle structure and primary 
motoneuron axon projections. (A-B) Longitudinal histological sections, HE stained. At 4 dpf, 
muscle fibres in fas/fasl-MO injected larvae are disorganized, undulated and oriented in opposite 
directions (B, arrowheads) in comparison to ctrl-MO injected larvae (A). (C-D) Axonal projections 
of primary motoneurons visualized by znp1 antibody present branching defects in fas/fasl-MO 
injected embryos at 24 hpf. (A-D) lateral views, anterior to the left, dorsal up. Scale bar: 100 µm. 
 
 
 
 Fig. 5 Analyses of notochord segmentation and vertebral formation following fas/fasl loss of 
function. (A-D) Calcein staining shows notochord segmentation by formation of calcified 
chordacentra in an antero-posterior fashion. The process of vertebrae formation starts at around 11 
dpf (3 mm) and is completed at around 18-21 dpf (7-9 mm). fas/fasl-MO-injected larvae at early (B-
B’ higher magnification) and complete vertebral mineralization (arrows, D) show significant defects 
in vertebrae formation with extensive vertebrae fusion in comparison to ctrl-MO injected larvae 
(A,A’ higher magnification, C). Scale bar: 100 µm. 
 
 
 Fig. 6 ntla and col2a1a are upregulated in fas/fasl-MO injected embryos. (A-B) Q-PCR analysis 
of ntla (A) and col2a1a (B) showing an upregulation.of the expression in fas/fasl-MO injected 
embryos for both genes. (C-D) WISH analysis showing persistent expression of the notochord 
marker ntla in the notochord of fas/fasl-MO injected embryos at 24 hpf (D) compared to control 
embryos (C). (E-F) WISH analysis showing persistent expression of the chordamesoderm marker 
col2a1a in the peri-norochordal sheath of fas/fasl-MO injected embryos (F, arrowheads) compared 
to control embryos in which col2a1a expression normally decreases at 48 hpf (E, arrowheads).  
 
 Suppl. Fig. S1 Validation and specificity of fas- and fasl-MOs. For the in-vivo test of the 
specificity of fasl-MO, a fasl-EGFP sensor has been generated. The pCS2+ construct containing the 
sequence recognized by the fasl-MO fused with the EGFP open reading frame is used for injection 
experiments with ctrl-MO or with the fasl-MO. (A-A’) Embryos at 24 hpf: EGFP-positive cells in 
the trunk and in the yolk epithelium following co-injection of the sensor and the control-MO. (B-B’) 
The complete absence of GFP expression when the sensor is co-injected with fasl-MO confirms the 
specificity of the ATG targeting morpholino action. (D-E’) Same experiments have been performed 
to in-vivo test the specificity of the fas-MO1. In A,B,D,E embryos are visualized under normal light, 
in A’,B’,D’,E’ under fluorescent light. (C) RT-PCR on control and splice-fasl-MO injected embryos 
at 24 hpf. RT-PCR primers are designed in exon 1 and exon 2 respectively; the amplification 
product is present in ctrl-MO injected embryos, while it is too large to be amplified in splice-fasl-
MO injected embryos, confirming the intron retention. (F) RT-PCR performed on control and 
splice-fas-MO injected embryos at 24 hpf. RT-PCR primers are designed in exon 1 and exon 3 
respectively. The amplification product, that comprehends the second exon, is 326 bp in ctrl-MO 
injected embryos, while a band at 174 bp (arrowhead) is detected in splice-fas-MO injected 
embryos, confirming the skipping of the second exon (150 bp).  
 
Suppl. Fig. S2 Vessel formation is comparable in control and fas/fasl-MO fliI:EGFP-trangenic 
injected embryos. Visible (A-B) and fluorescent images (A'-B') of EGFP-vessels visualized in 
control (A-A') and fas/fasl-MO (B-B')  injected embryos at 3 dpf  . 
 
 
Movie 1-Movie 2 fas/fasl-MO injected larvae present reduced motility after 48 hpf. Larvae at 6 
dpf have been tested with a tactile stimulus response assay. fas/fasl-MO injected larvae (Movie 2) 
are less sensitive to tactile stimuli than controls (Movie 1) and do not swim away when touched. 
 
 
Movie 3 Partial rescue of the motility of fas/fasl-MO injected larvae by means of the fasl 
mRNA injection. Larvae at 6 dpf have been tested with a tactile stimulus response assay. fas/fasl-
MO larvae have been injected with fasl full lenght mRNA. 55% (N=70) of the co-injected larvae 
partially rescued the immotile phenotype and swim away when stimulated.  
 
